Publication date: November 16, 2026
Online sales of semaglutide and other active substances in Poland – regulatory exposure for sellers, marketplaces, advertisers and logistics operators
Vials of semaglutide and other peptides are sold online in Poland as “research chemicals” and delivered to parcel lockers without a prescription. The label is meant to keep the product outside pharmaceutical law. It does not: under EU and Polish law the classification of a product follows its presentation and its effect, not the seller’s disclaimer. For businesses, the practical question is therefore not whether this trade is legal, but who in the chain – seller, marketplace, advertiser, influencer, payment or logistics provider – carries the criminal, administrative and civil risk, and how quickly Polish enforcement tools are catching up.
Online sales of active substances within the meaning of Article 2(38c) of the Polish Pharmaceutical Law[1] have grown rapidly over the last few years. E-commerce allows sellers to reach a wide audience with substances of high biological activity: hormones, peptides, metabolic agents (such as semaglutide and tirzepatide), nootropics and anabolic compounds. The legality of this trade in Poland is governed by pharmaceutical, medical and criminal law.
The business model discussed here consists in placing on the market substances with a documented therapeutic or physiological effect while avoiding the requirements of the Pharmaceutical Law by means of a purely formal, linguistic device: the goods are described as “not for human consumption”, a “laboratory reagent”, a “substance for scientific purposes” or a “collector’s item”. Semaglutide, the active substance of authorised medicinal products such as Ozempic, Wegovy and Rybelsus, is a representative example. Alongside the legal pharmaceutical supply chain there is a grey online market in which semaglutide is sold as a lyophilised powder in vials labelled “for research purposes only”.
This raises a classification question with direct commercial consequences. The definition of a medicinal product (Article 2(32) of the Pharmaceutical Law) is based on the properties of the product – presented or actual – for preventing or treating disease. Marketing a substance with a proven biological effect under the guise of a chemical reagent is an attempt to circumvent administrative and criminal rules. In practice it creates an area of legal uncertainty in which freedom of economic activity and the free movement of goods meet the overriding priority of protecting public health.
The illegal trade in substances such as semaglutide in the Polish digital space has taken the form of an organised practice built on circumventing regulation. The number of offers to buy these sought-after substances without a prescription is rising sharply. Customers are directed to websites and social media profiles where they can order products with delivery straight to a parcel locker, which gives the buyer a sense of convenience and apparent discretion. The phenomenon is part of a wider European trend of illegal distribution of GLP-1 receptor agonists, against which the European Medicines Agency (EMA)[2], the World Health Organization (WHO) and the Polish authorities – the Chief Pharmaceutical Inspectorate (GIF) and the Office for Registration of Medicinal Products (URPL) – have issued public warnings.
The key to the model is the so-called “loophole”: products are labelled and positioned as “research substances”. Sellers offer them as “research peptides” or “research raw materials”, which is formally intended to remove responsibility for selling a medicinal product for human use. At the same time, the entire marketing setting – graphics, wording and tone of communication – clearly suggests a weight-loss effect and directly alludes to authorised prescription medicines. This allows sellers to sidestep the strict rules on the distribution of prescription-only medicines and makes it harder for the authorities to shut the activity down immediately.
The model carries direct and serious risks for the health and life of consumers. A person buying from an illegal source has no guarantee as to purity, actual composition, concentration or dose. The products are outside any quality oversight; vials may contain harmful excipients or contaminants, or doses different from those declared, which can lead to serious medical complications. In addition, transport outside a controlled cold chain may degrade the active substance, so that the final product is not only illegal but may also be ineffective or unsafe. For legitimate businesses, every such incident is also a reputational risk for the brand name that the illegal offer imitates.
Classification as a medicinal product rests on two independent limbs derived from Article 1(2) of Directive 2001/83/EC[3] and Article 2(32) of the Pharmaceutical Law[4]: the presentation test and the function test. The first concerns how the product is perceived externally and, according to the Court of Justice of the European Union (CJEU), must be interpreted broadly. A product is a medicinal product by presentation if its packaging, leaflet, form or advertising gives an averagely well-informed consumer the impression that it has therapeutic or prophylactic properties (Case 227/82, Van Bennekom[5]). The pharmaceutical form, such as capsules or tablets, is strong evidence of the seller’s intention to market the product as a medicinal product, but it is not conclusive in itself. The Court confirmed this in Case C-369/88, Delattre[6], which concerned products sold by mail order and labelled as not being medicinal products. It added that such a statement is evidence which the national court may take into account, but is not in itself conclusive – a point of direct relevance to “research use only” disclaimers. The Polish Supreme Administrative Court has reasoned along the same lines in a food supplement labelling case: a product to which disease prevention or treatment properties are attributed is not a food supplement but a medicinal product[7]. On that basis the court upheld a fine imposed by the sanitary authorities, and confirmed by the Chief Sanitary Inspector, for labelling that suggested such properties.
The function test refers to the actual biological effect of the product on the human body, regardless of promotional claims or the manufacturer’s declarations. Here the classifying authority, including the URPL, cannot base its decision solely on the presence or quantity of a given active substance. The assessment must be made case by case, taking account of all the characteristics of the product. According to the CJEU, a product is not a medicinal product by function where, having regard to its composition, including its content of active substances, and if used as intended, it is incapable of appreciably restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action[8]. This requires a detailed analysis of biological properties and of the real impact of the substance on physiological processes. The CJEU has clarified the notion of “pharmacological action” in Case C-308/11, Chemische Fabrik Kreussler[9]: the substance does not have to interact with a cellular constituent of the user’s own body, and interaction with any cellular constituent present in the body, such as bacteria, may be sufficient. It has also held that substances which merely modify physiological functions without being capable of any beneficial effect on human health, and which are consumed solely to induce intoxication, are not medicinal products (Joined Cases C-358/13 and C-181/14, D. and G.[10]). That limitation does not assist sellers of semaglutide: it is the active substance of authorised medicines with an established therapeutic effect.
The relationship between the medicinal product regime and other regulatory regimes is governed by the conflict rule in Article 2(2) of Directive 2001/83/EC, mirrored in Article 3a of the Pharmaceutical Law. Where a product, taking into account all its characteristics, may fall both within the definition of a medicinal product and within that of another product category – for example a cosmetic, a medical device or a food supplement – the medicinal product rules prevail. The CJEU has made clear that this rule applies to products whose status as a medicinal product has been scientifically established, not to products for which it merely cannot be excluded (Case C-140/07, Hecht-Pharma[11]). The purpose is to ensure a high level of public health protection by subjecting such products to the authorisation and control procedures of the pharmaceutical market.
Offering a substance with the annotation “research material” or “for laboratory use” does not automatically release the seller from the requirements of Polish law. Under Article 2(38) of the Pharmaceutical Law, a substance is any matter of human, animal, plant or chemical origin. The classification of the goods depends on their actual intended use, presentation and biological profile. Labelling a product “for research purposes” therefore does not prevent the authorities from treating it as a medicinal product, a food supplement or a novel food if the circumstances show that it is intended for consumption or use in humans.
If the substance offered has properties for preventing or treating disease, or is presented in a way that suggests such an effect (for example through dosing information, instructions for use or social media advertising), it is subject to the Pharmaceutical Law. Placing a medicinal product on the market without a marketing authorisation is a criminal offence (Article 124 of the Pharmaceutical Law). A declaration that the product is “intended solely for research” is likely to be treated as an attempt to circumvent the law where the seller’s overall conduct shows commercial distribution to consumers.
Trade in genuine research substances and chemicals is subject to separate EU and national chemical safety rules, in particular the REACH[12] and CLP[13] Regulations. A seller of chemicals intended for laboratory research must classify and label them correctly and provide a safety data sheet. Where the substance is psychoactive, the Act on Counteracting Drug Addiction[14] applies irrespective of the trade name or declared research status, with criminal sanctions and administrative measures enforced by the State Sanitary Inspection. For legitimate laboratory suppliers the point is practical: selling to verified professional customers, with proper documentation, is what distinguishes a research chemical business from a disguised consumer channel.
Distribution of semaglutide preparations outside the official pharmacy channel takes place largely online. Distributors categorise products as “research peptides” or “substances for laboratory use”, or add a “research only” clause. The supply chain is optimised for discretion and convenience: orders are placed through web shops and social media profiles, and physical delivery is made through parcel lockers or couriers, which makes it difficult for supervisory authorities to inspect consignments at the delivery stage and removes any check of the buyer’s age or identity. Storage of consignments in parcel lockers at extreme temperatures (summer heat or winter frost) may additionally degrade peptides, so that the user may inject a degraded product.
On the marketing side, sellers use several persuasion strategies which, despite formal “research use” disclaimers, clearly suggest a weight-loss and therapeutic effect. Advertising is optimised for search phrases such as “Ozempic alternative” or “semaglutide without prescription” and supported by promotional content on social media and internet forums. Price comparison tools and informal recommendation marketing (for example endorsement by a well-known influencer) create an impression that the purchase is common, accessible and relatively safe, although the product in fact requires medical supervision and a prescription. Advertising medicinal products that are not authorised in Poland is itself an offence (Article 129 of the Pharmaceutical Law), which is directly relevant for agencies, publishers and influencers.
The most complex dimension is cross-border import and falsification, in line with the global trend identified by the WHO and the EMA. The raw material or ready vials and pens reach the EU market mainly from third countries (including Asia), often bypassing EU customs procedures and pharmaceutical inspection. The products do not undergo mandatory testing of purity, concentration of the active substance or stability under cold chain conditions. Import outside the legal supply chain therefore carries a critical risk of contaminated, wrongly dosed or inactive products entering the market.
The starting point is the Pharmaceutical Law. Under Article 124, placing a medicinal product on the market, or storing it for that purpose, without a marketing authorisation is punishable by a fine, restriction of liberty or imprisonment for up to two years. Carrying on business in the trade of medicinal products without the required permit is a separate and more serious offence, punishable by a fine, restriction of liberty or imprisonment from three months to five years (Article 125(2)(2)). Retail trade in medicinal products is reserved to pharmacies (Article 68(1)), and mail-order sale is permitted only for non-prescription medicines and only by licensed pharmacies and pharmacy outlets (Article 68(3)). Prescription-only medicines such as semaglutide therefore cannot lawfully be sold by mail order at all. Supplying or storing falsified medicinal products or falsified active substances is subject to more severe penalties, up to five years’ imprisonment (Article 124b), which is directly relevant to illegal web shops offering imitation pens or substances that are falsely presented as to their identity or source.
The position of online intermediaries is governed by the Digital Services Act[15] together with national consumer protection law. The DSA maintains the principle that there is no general obligation to monitor content (Article 8). However, a hosting provider loses the liability exemption under Article 6 if, upon obtaining actual knowledge or awareness of the illegal nature of an offer (for example through a notice under Article 16), it fails to act expeditiously to remove or disable access to it. Online marketplaces must in addition verify the traceability of traders (Article 30). In Poland, the Act of 4 September 2026[16], in force since 6 November 2026, designated the President of the Office of Electronic Communications (UKE) as Digital Services Coordinator. The President of the Office of Competition and Consumer Protection (UOKiK) is the competent authority for the obligations of online platforms that allow consumers to conclude distance contracts with traders (Chapter III, Section 4 of the DSA, which includes trader traceability) and for other DSA infringements that harm consumer interests. In this respect online marketplaces are therefore supervised by UOKiK. Independently, UOKiK may impose significant fines for practices infringing collective consumer interests, and the Chief Pharmaceutical Inspector may order withdrawals and impose administrative fines under the Pharmaceutical Law.
Sellers also face liability under the Criminal Code for endangering life or health – in particular Article 165 § 1(2) (causing danger to the life or health of many persons by placing on the market substances harmful to health or pharmaceutical products that do not meet quality requirements) and Article 160 (exposing a person to direct danger of loss of life or serious injury). Describing products as “research peptides” does not release a business from criminal liability on the basis of a mistake of law or an appearance of legality where the products are in fact intended and advertised for human use. Finally, entities offering illegal preparations are fully liable in tort to consumers for damage to health caused by a product that is substandard, toxic or of unknown origin.
The regulatory gap in the online trade in active substances does not result from a lack of rules but from their fragmentation and from enforcement difficulties. The core problem is a grey zone that exploits the “research purposes” classification. The State Pharmaceutical Inspection and law enforcement authorities face evidentiary barriers and lengthy procedures when dealing with operators who quickly change domains, jurisdictions and corporate names. A regime based on reacting after a product has been placed on the market is not effective enough against mass, automated e-commerce.
The legislative landscape is changing. In addition to the September 2026 act establishing national DSA oversight, Parliament has adopted a further amendment to the Act on the Provision of Electronic Services, the Act of 22 October 2026[17]. It introduces orders to disable access to illegal content, issued by the President of UKE (or by the Chairman of the National Broadcasting Council for video-sharing platforms), and a register of internet domains used to disseminate such content, kept by the President of UKE. Internet access providers will have to block a registered domain within 48 hours. The act was sent to the President of Poland, whose decision was pending at the time of writing, and is to enter into force three months after publication.
For the trade discussed here the new mechanism has an important limit. Orders may be issued only for content linked to a closed catalogue of offences, and that catalogue does not include the offences under the Pharmaceutical Law or Article 165 of the Criminal Code. An illegal offer of “research” semaglutide can therefore be caught only indirectly, for example where it involves fraud (Article 286 of the Criminal Code) or goods bearing a counterfeit trade mark (Article 305 of the Industrial Property Law). Applications may be filed by a prosecutor, the Police, the National Revenue Administration, copyright holders and service recipients; the Chief Pharmaceutical Inspector is not named among the applicants. In our view, sector-specific measures therefore remain necessary: clear powers for the Chief Pharmaceutical Inspector to initiate rapid blocking of sites and domains offering illegal medicines, and rules on trade in peptides and other biologically active substances making clear that a “research use” declaration does not displace classification as a medicinal product where the presentation points to a therapeutic purpose.
A systemic response also requires close inter-agency cooperation and integrated controls at the EU’s borders. We recommend dedicated task forces bringing together the GIF, the National Revenue Administration (KAS), the Police and UOKiK to monitor cross-border courier and postal consignments delivered to parcel lockers. Legal changes should be complemented by public education, conducted together with the medical and pharmacists’ self-governing bodies, on the health risks of products of unknown origin and on using only authorised online pharmacies bearing the common EU logo.
State of the law as at 10 November 2026. This article is for general information and does not constitute legal advice.
[1] Act of 6 September 2001 – Pharmaceutical Law (consolidated text: Journal of Laws [Dz. U.] of 2026, item 612, as amended); hereinafter the “Pharmaceutical Law”.
[2] European Medicines Agency and Heads of Medicines Agencies, “Warning about sharp rise in illegal medicines sold in the EU”, September 2025.
[3] Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ L 311, 28.11.2001, p. 67). The Directive is due to be replaced by a new directive under the EU pharmaceutical package; the Council adopted its first-reading position on 28 September 2026 and the final adoption steps were under way at the time of writing.
[4] Under Article 2(32) of the Pharmaceutical Law, a medicinal product is a substance or combination of substances presented as having properties for preventing or treating disease in humans or animals, or administered with a view to making a diagnosis or to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action.
[5] Judgment of the Court of Justice of 30 November 1983, Case 227/82, Van Bennekom, ECLI:EU:C:1983:354, paras 17-19 (decided under Directive 65/65/EEC, the predecessor of Directive 2001/83/EC).
[6] Judgment of the Court of Justice of 21 March 1991, Case C-369/88, Delattre, ECLI:EU:C:1991:137, paras 38-41 (also decided under Directive 65/65/EEC).
[7] Judgment of the Supreme Administrative Court (NSA) of 1 September 2015, II OSK 14/14, LEX no. 1987032.
[8] Judgment of the Court of Justice of 15 January 2009, Case C-140/07, Hecht-Pharma, ECLI:EU:C:2009:5, paras 39-42 and point 3 of the operative part.
[9] Judgment of the Court of Justice of 6 September 2012, Case C-308/11, Chemische Fabrik Kreussler, ECLI:EU:C:2012:548, paras 31-36.
[10] Judgment of the Court of Justice of 10 July 2014, Joined Cases C-358/13 and C-181/14, D. and G., ECLI:EU:C:2014:2060.
[11] Case C-140/07, Hecht-Pharma, cited above, paras 24-29 and point 1 of the operative part.
[12] Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH).
[13] Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures (CLP).
[14] Act of 29 July 2005 on Counteracting Drug Addiction (consolidated text: Journal of Laws of 2023, item 1939, as amended).
[15] Regulation (EU) 2022/2065 of the European Parliament and of the Council of 19 October 2022 on a Single Market For Digital Services (Digital Services Act).
[16] Act of 4 September 2026 amending the Act on the Provision of Electronic Services and certain other acts (Journal of Laws of 2026, item 1296), published on 6 October 2026; see the new Articles 15a and 15b of the Act on the Provision of Electronic Services.
[17] Act of 22 October 2026 amending the Act on the Provision of Electronic Services and certain other acts (Sejm print no. 2693, text finally adopted after consideration of the Senate’s amendments), adding Articles 11a-11s to the Act on the Provision of Electronic Services; not yet published at the time of writing.
KIELTYKA GLADKOWSKI is a Polish business law firm headquartered in Warsaw and Krakow, with a New York office under the iSTART1 brand. Building on a practice dating back to 1981, we advise clients in the following areas.
Select a practice area to learn more.
Service directory: kg-legal.eu/services